Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug

22-Mar-2012 - Xention Ltd. reported positive data today from a phase 1 trial of XEN-D0103 administered orally. The drug, a selective inhibitor of the cardiac potassium channel Kv1.5, was well tolerated and demonstrated good pharmacokinetic (PK) properties. The results support the continuing development of ...

Xention Participates in €12 Million Atrial Fibrillation Research Consortium

Consortium awarded five-year European Union grant under Seventh Framework programme

17-Mar-2011 - XENTION LTD announced that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the ‘European Network for Translational Research in Atrial Fibrillation’ (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF) research.The ...

Xention and Grünenthal enter Drug Discovery Collaboration in Ion Channel Research

Research collaboration to focus on development of novel pain therapeutics

17-Feb-2011 - XENTION LTD announced that it has entered into a Research Agreement with the Grünenthal Group. Under the terms of the Agreement, Xention and Grϋnenthal will combine their respective expertise in ion channel drug discovery and pain therapy to collaborate in the identification of new drugs to treat ...

Xention Receives Wellcome Trust Award For Atrial Fibrillation Programme

07-Jul-2009 - XENTION LTD announced that it had received a substantial award from the Wellcome Trust to support pioneering work on an exciting target for atrial fibrillation. The award, made under Wellcome’s Seeding Drug Discovery initiative, will provide up to £3 million to fund Xention’s IKACh programme ...

Xention Limited Builds Team with Appointment of Chief Medical Officer

10-Jun-2009 - Xention Ltd. announced the appointment of Dr Patrick Round as Chief Medical Officer and Head of Development. Dr Round has broad and substantial experience in development in both biotech and pharma, most notably as Senior Vice President at Cambridge Antibody Technology (CAT) where he was ...

Xention Limited Strengthens Team with New Director of Business Development

25-May-2009 - Xention Ltd announced the appointment of Dr Calum Graham as Director of Business Development. Dr Graham is an experienced business development executive with a strong scientific background and expert knowledge of the drug development process gained over nineteen years in the pharmaceutical ...

Xention Enters Drug Discovery Agreement with Ono Pharmaceutical Co., Ltd.

16-Mar-2009 - Xention Ltd announced that it has signed a Drug Discovery Agreement with Ono Pharmaceutical Co., Ltd. Under the terms of the Agreement, Xention will apply its proprietary ion channel drug discovery platform to the identification, design and synthesis of small molecules against ion channels ...

Xention Limited Appoints Dr Keith McCullagh as New Chairman of its Board

04-Feb-2009 - XENTION LTD announced the appointment of Dr Keith McCullagh as the new non-executive Chairman of its Board of Directors. Keith McCullagh is an experienced biotech entrepreneur. From 2003 until his retirement last year he was CEO of Santaris Pharma, the Danish RNA medicines company. From 2000 ...

Aureus Pharma licenses AurSCOPE Ion Channel Knowledgebase to Xention

30-Jun-2006 - Aureus Pharma announces that Xention, a drug discovery and development company focusing on ion channels, has licensed its AurSCOPE Ion Channel Knowledge database. Ion Channels are an important drug target class as they are involved in many physiological and pathophysiological processes, ...